Tuesday, May 05, 2020 10:12:54 PM
Compare the company descriptions:
Connectyx Technologies Holdings Group, Inc. is a global biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company's business model.
VS.
SunMed is a leading advisor to Life Science companies ranging from those still in clinical stage to those with commercial products on the market. We bring value to all stages of transactions, from initiation and sourcing, through closing. Our primary focus is on cross boarder licensing. Our management team has over 30 years of experience successfully completing transactions.
Connectyx Technologies Holdings Group, Inc. is a global biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company's business model.
VS.
SunMed is a leading advisor to Life Science companies ranging from those still in clinical stage to those with commercial products on the market. We bring value to all stages of transactions, from initiation and sourcing, through closing. Our primary focus is on cross boarder licensing. Our management team has over 30 years of experience successfully completing transactions.
Recent CUBT News
- Curative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research Agreement • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy • GlobeNewswire Inc. • 04/15/2026 12:08:00 PM
- Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting • GlobeNewswire Inc. • 03/23/2026 11:05:00 PM
- Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- Curative Biotechnology Announces Canadian Patent Allowance • GlobeNewswire Inc. • 01/23/2026 01:45:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 12/22/2025 06:40:01 PM
- Curative Biotechnology, Inc. Announces Letter to Shareholders • GlobeNewswire Inc. • 11/18/2025 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/01/2025 08:07:47 PM
